Mini-Focus on Acute Coronary SyndromesClinical ResearchAssociation Between Angiographic Complications and Clinical Outcomes Among Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome) Angiographic Substudy
Key Words
Abbreviations and Acronyms
Cited by (0)
The EARLY ACS trial was supported by Schering-Plough and Millennium Pharmaceuticals. All authors received research grant support from the sponsor of the trial, Merck-Schering Plough. Dr. Giugliano has received honoraria from Merck-Schering Plough as a consultant and for continuing medical education lectures. Dr. Newby has received research grant funding for EARLY ACS through Duke/Duke Clinical Research Institute from Merck-Schering Plough, Amgen, Inc., Amylin, Astra Zeneca, Eli Lilly, Daiichi-Sankyo, diaDexus, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, Murdock Study, Regado Biosciences, NHLBI, Novartis, Roche. Dr. Braunwald has received consulting fees, lecture fees, and grant support from Eli Lilly, Johnson & Johnson, Merck and Bayer. Dr. Califf has received consulting fees and grant support from, Amylin, Kowa Research Institute, Merck-Schering Plough, Nile, NITROX LLC, Parkview, Bristol Myers Squibb, Novartis, Orexigen Therapeutics, Pozen, Servier International, Johnson & Johnson, Roche, Merck, Regado, Bayer, and Web M.D. Dr. Harrington has received consulting fees, lecture fees, and grant support from Merck-Schering Plough, Sanofi, Lilly, Daiichi-Sankyo, Bristol-Myers Squibb, Novartis, AstraZeneca, Johnson & Johnson, Portola, Merck, Regado, and Web M.D. Dr. Gibson has received consulting fees from Merck-Schering Plough.